Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma

2016 ◽  
Vol 27 (2) ◽  
pp. 129-130
Author(s):  
A. Sahin
Cancer ◽  
2016 ◽  
Vol 123 (1) ◽  
pp. 131-137 ◽  
Author(s):  
Hannah Y. Wen ◽  
Melissa Krystel-Whittemore ◽  
Sujata Patil ◽  
Fresia Pareja ◽  
Zenica L. Bowser ◽  
...  

2015 ◽  
Vol 139 (12) ◽  
pp. 1546-1549 ◽  
Author(s):  
Philip E. Bomeisl ◽  
Cheryl L. Thompson ◽  
Lyndsay N. Harris ◽  
Hannah L. Gilmore

ContextOncotype DX (ODX) is a widely used commercial assay that estimates the risk of distant recurrence and may predict the benefit of chemotherapy in a subset of breast cancers. Some studies have shown the ability to predict Oncotype DX recurrence score (ODXRS), based on routinely reported pathologic features; however, there are limited data correlating specific histologic type of breast cancer to ODXRS.ObjectiveTo compare ODXRS to specific histologic types of breast cancer.DesignOne hundred eighty-four cases were sent for ODXRS testing and the results were compared with histologic type and grade.ResultsThe highest average ODXRS was seen in invasive ductal carcinoma with micropapillary features (29) followed by invasive ductal carcinoma not otherwise specified (mean = 19.4, SD = 11.6), invasive mucinous carcinoma (mean = 17.2, SD = 5.9), invasive lobular carcinoma (mean = 15.7, SD = 7.2), mixed ductal and lobular carcinoma (mean = 14.1, SD = 7.7), tubular carcinoma (10.0), and mixed ductal and mucinous carcinoma (mean = 8.0, SD = 4.2). Most tumors that had a high ODXRS were grade 3 invasive ductal carcinoma, representing 13 of a total of 20 cases (65%). Interestingly, 3 of the 4 cases of pure invasive mucinous carcinoma had an intermediate ODXRS.ConclusionsAlthough the numbers are small, our findings raise further awareness of the significance between histologic type and grade, and RS in breast cancer. In some special histologic types of breast cancer, particularly those considered to follow either an excellent or poor clinical course by histology alone, it is unclear whether the ODXRS results are as meaningful as in carcinomas of no special type. Further investigation with higher numbers and outcome data is needed.


2018 ◽  
Author(s):  
R Pajunk ◽  
J Barinoff ◽  
A Junker-Stein ◽  
S Aulmann ◽  
R Gruber ◽  
...  

2021 ◽  
Vol 12 (01) ◽  
pp. 25-26
Author(s):  
Katharina Arnheim

Gemäß Interimsanalyse der Studie RxPONDER kann bei postmenopausalen Frauen mit frühem Hormonrezeptor- (HR) positivem Brustkrebs und positivem Nodalstatus unabhängig von ihrem Oncotype DX Recurrence Score (RS) auf eine adjuvante Chemotherapie verzichtet werden. Prämenopausale Frauen dagegen profitieren von der Chemotherapie mit einer Verbesserung des invasiven krankheitsfreien (iDFS) und Gesamtüberlebens (OS).


2019 ◽  
Vol 45 (2) ◽  
pp. 134-140 ◽  
Author(s):  
Isaac Kim ◽  
Hee Jun Choi ◽  
Jai Min Ryu ◽  
Se Kyung Lee ◽  
Jong Han Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document